Infectious Disease
Expert guidance on antimicrobial stewardship, emerging infections, and complex infectious disease management.
Recent Discussions
Is there ever a role for the use of CMV immune globulin for treatment of CMV viremia and/or disease?
CMV immune globulin (CMVIG) should certainly not be first-line therapy for treating CMV syndromes. It can be considered for use in special circumstances when patients are intolerant to 1st or 2nd line therapy, they have resistant/refractory disease, or are at significant risk for morbidity in combin...
Should checking a urinalysis with reflex to culture be part of the standard work up for fever in an ICU patient with a urinary catheter?
Yes, as part of a broad workup for infectious and non-infectious causes of fever, and with many caveats. Patients in the ICU are at high risk for diagnosis with CAUTI, yet as I think you are applying, this is a difficult diagnosis to make given the inability of many patients to give a history (or fo...
What is the utility of granulocyte infusions in patients with neutropenia and severe infection?
Granulocyte transfusion is infrequently used for septic neutropenic patients given that the randomized trial (RING) that looked at this question did not show improved outcomes (with the caveat that the trial did not finish accrual (Price et al., PMID 26333778). Having said that, the criteria to cons...
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
Bacillus Calmette–Guérin (BCG) is the most widely used vaccine worldwide and has been used to prevent tuberculosis for a century. BCG also stimulates an anti-tumor immune response, which urologists have harnessed for the treatment of non-muscle-invasive bladder cancer. As rheumatologists, we occasio...
Do you treat Candida spp isolated from a bronchoalveolar lavage?
I would only treat if there was evidence of Candida infection from another source/location (at the same time).
Do you avoid performing urine microscopy in patients with AKI who have COVID-19 given concern for potential aerosolization?
No. The risk is very low to non-existent. At the beginning of the epidemic we were doing that but the evidence now is not supporting that practice.
Are there clinical scenarios in which you would start empiric treatment for pulmonary TB without microbiologic confirmation?
Yes, there are a few situations. One of them being pauci-bacillary TB in which you catch TB very early on its course hence your micro/cultures will be negative. CT will demonstrate micronodules. This is a diagnosis of exclusion and requires the right clinical setting (high-risk patient, from an ende...
Would you treat a sputum culture positive for Aspergillus niger despite an atypical CT chest and a negative serum galactomannan in an immunosuppressed patient who is too high risk for bronchoscopy?
How do you apply the CDC PrEP guidelines for cisgender women, particularly when faced with underreported risk behaviors or uncertain partner HIV status?
This can be quite difficult, especially in places like where I live in Texas, where PrEP literacy is low. There is still a lot of education that needs to take place in the community about how HIV is still a threat that you can do something about, particularly for women. On a global basis, getting th...
In which patients do you prefer daily standard three-drug therapy for non-cavitary pulmonary MAC as opposed to three times a week dosing?
Generally, if non-cavitary disease I favor thrice weekly therapy. However, if widespread non cavitary disease or immunosuppressed, I may choose daily dosing.